Is the Way to Someone's Heart Through Their Stomach?: The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure

Circulation: Heart Failure

Volumn 10, Issue 10, 2017, Pages

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antidiabetic drugs; cyclic AMP; diabetes mellitus; heart failure; incretins

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; LIXISENATIDE; PHOSPHODIESTERASE INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DEPRESSED BLOOD PRESSURE; DIABETES MELLITUS; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; KIDNEY FUNCTION; METABOLISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SODIUM RETENTION; SODIUM URINE LEVEL; STOMACH; AGONISTS; DRUG EFFECT; HEART; HEART CONTRACTION; HEART RATE; KIDNEY; NATRIURESIS; PATHOPHYSIOLOGY; PHARMACOLOGY;

CYCLIC AMP; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART; HEART FAILURE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; KIDNEY; MYOCARDIAL CONTRACTION; NATRIURESIS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VENTRICULAR REMODELING;

EID: 85040793458     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.004551     Document Type: Article

References (64)

1. Ussher JR, Drucker DJ, Cardiovascular actions of incretin-based therapies. Circ Res 2014 114 1788 1803. doi: 10.1161/CIRCRESAHA.114.301958.
2. Tiwari S, Riazi S, Ecelbarger CA, Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 2007 293 F974 F984. doi: 10.1152/ajprenal.00149.2007.
3. Bełtowski J, Rachańczyk J, Włodarczyk M, Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res 2013 2013 628628. doi: 10.1155/2013/628628.
4. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C, Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004 89 3055 3061. doi: 10.1210/jc.2003-031403.
5. Lovshin JA, Rajasekeran H, Lytvyn Y, Lovblom LE, Khan S, Alemu R, Locke A, Lai V, He H, Hittle L, Wang W, Drucker DJ, Cherney DZI, Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α(1-67) in patients with type 2 diabetes. Diabetes Care 2017 40 1073 1081. doi: 10.2337/dc17-0061.
6. DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin G, Zhuang S, Zhao TC, Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab 2014 307 E630 E643. doi: 10.1152/ajpendo.00109.2014.
7. Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC, Chattipakorn N, Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. Exp Physiol 2015 100 667 679. doi: 10.1113/EP085108.
8. Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM, Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS One 2015 10 e0130894. doi: 10.1371/journal.pone.0130894.
9. Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB, Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. J Card Fail 2012 18 804 809. doi: 10.1016/j.cardfail.2012.07.009.
10. Packer M, Anker SD, Butler J, Filippatos G, Zannad F, Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017 2 1025 1029. doi: 10.1001/jamacardio.2017.2275.
11. Mudaliar S, Alloju S, Henry RR, Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? a unifying hypothesis. Diabetes Care 2016 39 1115 1122. doi: 10.2337/dc16-0542.
12. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M, Antihypertensive treatment and development of heart failure in hypertension: A Bayesian network meta-Analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011 171 384 394. doi: 10.1001/archinternmed.2010.427.
13. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720.
14. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925.
15. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 375 311 322. doi: 10.1056/NEJMoa1603827.
16. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 375 1834 1844. doi: 10.1056/NEJMoa1607141.
17. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015 373 2247 2257. doi: 10.1056/NEJMoa1509225.
18. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 369 1317 1326. doi: 10.1056/NEJMoa1307684.
19. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015 373 232 242. doi: 10.1056/NEJMoa1501352.
20. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet 2015 385 2067 2076. doi: 10.1016/S0140-6736(14)62225-X.
21. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2016 316 500 508. doi: 10.1001/jama.2016.10260.
22. Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B, Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014 13 33. doi: 10.1186/1475-2840-13-33.
23. Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J, Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: A observational sudy. Diabetes Care 2016 39 726 734. doi: 10.2337/dc15-0764.
24. Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH, Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: A retrospective cohort study. Ann Intern Med 2016 164 705 714. doi: 10.7326/M15-2568.
25. Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM, No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan. Int J Cardiol 2016 220 14 20. doi: 10.1016/j.ijcard.2016.06.125.
26. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT, Long-Term effects of intensive glucose lowering on cardiovascular outcomes. New Engl J Med 2011 364 818 828
27. Gilbert RE, Krum H, Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015 385 2107 2117. doi: 10.1016/S0140-6736(14)61402-1.
28. Roumie CL, Min JY, D'Agostino McGowan L, Presley C, Grijalva CG, Hackstadt AJ, Hung AM, Greevy RA, Elasy T, Griffin MR, Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: A cohort study. J Am Heart Assoc 2017 6 e005379. doi: 10.1161/JAHA.116.005379.
29. Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S, The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-Analysis of published observational studies. BMC Cardiovasc Disord 2014 14 129. doi: 10.1186/1471-2261-14-129.
30. McAlister FA, Eurich DT, Majumdar SR, Johnson JA, The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008 10 703 708. doi: 10.1016/j.ejheart.2008.05.013.
31. Chen HH, Oh KY, Terzic A, Burnett JC Jr, The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure. Eur J Heart Fail 2000 2 33 40
32. Aoyama M, Kawase H, Bando YK, Monji A, Murohara T, Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 axis. Circ Heart Fail 2016 9 e002081. doi: 10.1161/CIRCHEARTFAILURE.115.002081.
33. Xiao YF, Nikolskaya A, Jaye DA, Sigg DC, Glucagon-like peptide-1 enhances cardiac L-Type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011 10 6. doi: 10.1186/1475-2840-10-6.
34. Sassoon DJ, Tune JD, Mather KJ, Noblet JN, Eagleson MA, Conteh AM, Sturek JT, Goodwill AG, Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction. Diabetes 2017 66 2230 2240. doi: 10.2337/db16-1206.
35. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L, Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 2017 16 6. doi: 10.1186/s12933-016-0490-6.
36. Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y, Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2013 304 H131 H141. doi: 10.1152/ajpheart.00609.2012.
37. Wallner M, Kolesnik E, Ablasser K, Khafaga M, Wakula P, Ljubojevic S, Thon-Gutschi EM, Sourij H, Kapl M, Edmunds NJ, Kuzmiski JB, Griffith DA, Knez I, Pieske B, von Lewinski D, Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. J Mol Cell Cardiol 2015 89 p t B 365 375. doi: 10.1016/j.yjmcc.2015.09.018.
38. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991 325 1468 1475. doi: 10.1056/NEJM199111213252103.
39. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006 12 694 699. doi: 10.1016/j.cardfail.2006.08.211.
40. Nathanson D, Ullman B, Löfström U, Hedman A, Frick M, Sjöholm A, Nyström T, Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012 55 926 935. doi: 10.1007/s00125-011-2440-x.
41. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004 109 962 965. doi: 10.1161/01.CIR.0000120505.91348.58.
42. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S, Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-Analysis. Diabetes Res Clin Pract 2015 110 26 37. doi: 10.1016/j.diabres.2015.07.015.
43. Fujita H, Taniai H, Murayama H, Ohshiro H, Hayashi H, Sato S, Kikuchi N, Komatsu T, Komatsu K, Komatsu K, Narita T, Yamada Y, DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr J 2014 61 159 166
44. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010 363 905 917. doi: 10.1056/NEJMoa1003114.
45. Vazir A, Claggett B, Jhund P, Castagno D, Skali H, Yusuf S, Swedberg K, Granger CB, McMurray JJ, Pfeffer MA, Solomon SD, Prognostic importance of temporal changes in resting heart rate in heart failure patients: An analysis of the CHARM program. Eur Heart J 2015 36 669 675. doi: 10.1093/eurheartj/ehu401.
46. Hamill V, Ford I, Fox K, Böhm M, Borer JS, Ferrari R, Komajda M, Steg PG, Tavazzi L, Tendera M, Swedberg K, Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med 2015 128 1102 1108.e6. doi: 10.1016/j.amjmed.2015.04.042.
47. Birnbaum Y, Castillo AC, Qian J, Ling S, Ye H, Perez-Polo JR, Bajaj M, Ye Y, Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther 2012 26 445 456. doi: 10.1007/s10557-012-6409-x.
48. Wu T, Trahair LG, Bound MJ, Deacon CF, Horowitz M, Rayner CK, Jones KL, Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with type 2 diabetes: A potential role for glucose-dependent insulinotropic polypeptide? Diabet Med 2015 32 595 600. doi: 10.1111/dme.12622.
49. Zhou X, Huang CH, Lao J, Pocai A, Forrest G, Price O, Roy S, Kelley DE, Sullivan KA, Forrest MJ, Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovasc Diabetol 2015 14 29. doi: 10.1186/s12933-015-0194-3.
50. Hadad I, Veithen A, Springael JY, Sotiropoulou PA, Mendes Da Costa A, Miot F, Naeije R, De Deken X, Entee KM, Stroma cell-derived factor-1α signaling enhances calcium transients and beating frequency in rat neonatal cardiomyocytes. PLoS One 2013 8 e56007. doi: 10.1371/journal.pone.0056007.
51. Kubota A, Takano H, Wang H, Hasegawa H, Tadokoro H, Hirose M, Kobara Y, Yamada-Inagawa T, Komuro I, Kobayashi Y, DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Mol Cell Cardiol 2016 91 72 80. doi: 10.1016/j.yjmcc.2015.12.026.
52. Ballagi-Pordány G, Koltai MZ, Aranyi Z, Pogátsa G, Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs. Diabetes Res Clin Pract 1991 11 47 52
53. Khatib SY, Boyett MR, Effects of glyburide (glibenclamide) on myocardial function in Langendorff perfused rabbit heart and on myocardial contractility and slow calcium current in guinea-pig single myocytes. Mol Cell Biochem 2003 242 81 87
54. Uchida K, Ogino K, Shimoyama M, Hisatome I, Shigemasa C, Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts. Eur J Pharmacol 2000 400 113 119
55. Lucchesi BR, Medina M, Kniffen FJ, The positive inotropic action of insulin in the canine heart. Eur J Pharmacol 1972 18 107 115
56. von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Mächler H, Rössl U, Pieske B, Glucose-Transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 2010 59 1020 1028. doi: 10.1016/j.metabol.2009.10.025.
57. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ, The effect of statin therapy on heart failure events: A collaborative meta-Analysis of unpublished data from major randomized trials. Eur Heart J 2015 36 1536 1546. doi: 10.1093/eurheartj/ehv072.
58. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 357 2248 2261. doi: 10.1056/NEJMoa0706201.
59. Veterans Administration Cooperative Study Group on Antihypertensive Agents Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970 213 1143 1152. doi: 10.1001/jama.1970.03170330025003.
60. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL, PRAISE-2 Study Group Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 Study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail 2013 1 308 314. doi: 10.1016/j.jchf.2013.04.004.
61. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003 5 659 667. doi: 10.1016/S1388-9842(03)00163-6.
62. Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, ALLHAT Collaborative Research Group Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med 2002 137 5 part 1 313 320
63. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986 314 1547 1552. doi: 10.1056/NEJM198606123142404.
64. Carbone S, Arena R, Abbate A, Lack of benefit for liraglutide in heart failure. JAMA 2016 316 2429. doi: 10.1001/jama.2016.15387.